SG Americas Securities LLC Acquires 376,623 Shares of Organogenesis $ORGO

SG Americas Securities LLC raised its holdings in Organogenesis (NASDAQ:ORGO) by 199.4% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 565,501 shares of the company’s stock after buying an additional 376,623 shares during the quarter. SG Americas Securities LLC owned 0.45% of Organogenesis worth $2,929,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. First Light Asset Management LLC increased its stake in shares of Organogenesis by 10.6% in the 3rd quarter. First Light Asset Management LLC now owns 7,497,911 shares of the company’s stock valued at $31,641,000 after acquiring an additional 720,748 shares in the last quarter. Assenagon Asset Management S.A. lifted its position in shares of Organogenesis by 14.0% during the 4th quarter. Assenagon Asset Management S.A. now owns 5,535,334 shares of the company’s stock valued at $28,673,000 after acquiring an additional 680,392 shares during the period. Intrepid Family Office LLC boosted its stake in Organogenesis by 10.0% during the second quarter. Intrepid Family Office LLC now owns 110,000 shares of the company’s stock worth $403,000 after acquiring an additional 10,000 shares in the last quarter. Creative Planning grew its holdings in Organogenesis by 84.5% in the second quarter. Creative Planning now owns 35,392 shares of the company’s stock worth $130,000 after purchasing an additional 16,205 shares during the period. Finally, Strs Ohio acquired a new stake in Organogenesis in the first quarter worth $105,000. 49.57% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, Director Michael Joseph Driscoll purchased 10,000 shares of the business’s stock in a transaction on Monday, March 9th. The stock was acquired at an average price of $2.67 per share, for a total transaction of $26,700.00. Following the purchase, the director owned 225,707 shares of the company’s stock, valued at approximately $602,637.69. This trade represents a 4.64% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 33.00% of the company’s stock.

Organogenesis Stock Performance

ORGO opened at $2.24 on Friday. The company has a current ratio of 3.62, a quick ratio of 3.32 and a debt-to-equity ratio of 0.04. The company’s fifty day moving average price is $3.21 and its two-hundred day moving average price is $4.19. Organogenesis has a 1-year low of $2.21 and a 1-year high of $7.08. The company has a market cap of $288.15 million, a price-to-earnings ratio of 28.00 and a beta of 1.48.

Organogenesis (NASDAQ:ORGO) last issued its quarterly earnings data on Thursday, February 26th. The company reported $0.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.21 by $0.10. The firm had revenue of $225.61 million during the quarter, compared to analysts’ expectations of $172.68 million. Organogenesis had a net margin of 5.32% and a return on equity of 21.41%. On average, analysts expect that Organogenesis will post -0.07 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

ORGO has been the topic of several research reports. Wall Street Zen upgraded shares of Organogenesis from a “hold” rating to a “buy” rating in a report on Sunday, March 8th. Weiss Ratings upgraded Organogenesis from a “sell (d+)” rating to a “hold (c)” rating in a research note on Friday, February 27th. Finally, BTIG Research reaffirmed a “buy” rating and set a $8.00 price target on shares of Organogenesis in a research note on Thursday, March 26th. Two equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $8.50.

Organogenesis Company Profile

Organogenesis Inc operates as a regenerative medicine company focused on the development, manufacturing and commercialization of therapeutic solutions for wound care, surgical repair and sports medicine. The company’s product portfolio addresses a range of acute and chronic tissue repair needs, leveraging bioengineered skin substitutes, human placental-derived products and other allografts designed to promote healing and reduce scarring. Organogenesis markets its therapies to hospitals, outpatient clinics, wound care centers and other healthcare providers.

Key offerings include Apligraf, a living skin substitute for treatment of diabetic foot ulcers and venous leg ulcers; Dermagraft, a cryopreserved human fibroblast-derived dermal substitute; Grafix, a placental membrane allograft for complex and chronic wounds; and TheraSkin, a cryopreserved human skin allograft used in surgical and reconstructive procedures.